PUBLISHED ASSESSMENT

These Infections Are Linked to 12% of New Cancer Cases

This compact public record contains an assessment and source links. It does not contain article text, reader identity, browsing history, or private notes.

Open original article

The article’s central figures and descriptions are strongly supported by IARC and authoritative health sources. It appropriately explains latency, multifactorial causation, and prevention. Important gaps include the study’s modeling uncertainty, stark geographic inequalities, H. pylori treatment caveats, and support for the claimed steep U.S. hepatitis B vaccination decline. Attribution is generally clear, but the underlying methodology and complete infection list are not presented.

Evidence support

Strong (84/100)

IARC materials support the central estimate that infections caused approximately 2.3 million, or 12%, of new cancer cases worldwide in 2024.
The reported contributions of H. pylori, HPV, HBV, HCV, and EBV closely match IARC figures.
NCI and CDC sources corroborate the described cancer links, mechanisms, and preventive effects of vaccination, antimicrobial treatment, and HIV therapy.
The claim that U.S. newborn hepatitis B vaccination declined steeply needs qualification: national CDC survey data show a 1.8-percentage-point cohort decline and a three-cohort downward trend.

Balance & context

Substantial (73/100)

The article clearly states that most infected people do not develop cancer, latency can last years, and infection often interacts with genetic and environmental factors.
It distinguishes established prevention tools from infections for which no vaccine exists.
It omits major geographic and socioeconomic context: more than three quarters of attributable cancers occurred in low- and middle-income countries, and Eastern Asia represented 42% of the burden.
The H. pylori discussion does not note that broad population testing and eradication remain debated and can contribute to antibiotic resistance.

Transparency

Substantial (74/100)

The article provides a named author, publication date, named expert sources, affiliations, direct quotations, and links to IARC and supporting health sources.
It identifies the underlying IARC report and its publication in Lancet Oncology.
It does not explain how attributable fractions were calculated, provide uncertainty intervals, or clearly distinguish modeled estimates from observed case counts.
Seven of the twelve infections are not individually identified, limiting readers’ ability to inspect the complete finding.

Confidence and coverage

Confidence in this analysis: Moderate confidence

Evidence coverage: Substantial coverage

The full Lancet Oncology article was not accessible, so its detailed methods, uncertainty intervals, and limitations could not be directly examined.
The assessment relied on IARC’s press release and technical Q&A for the study’s principal estimates.

The main findings were corroborated through authoritative IARC, CDC, NIH/NCI, and peer-reviewed sources.
Confidence is limited by lack of direct access to the full Lancet Oncology methods and uncertainty analysis.

Sources considered

Global burden of cancer attributable to infections in 2024: Press Release No. 387 — Primary institutional release providing the overall estimate, infection-specific case counts, full infection list, and regional inequalities.
Global burden of cancer attributable to infections in 2024: Questions and Answers — Provides cancer associations, prevention measures, regional differences, and information on newly included links.
Vaccination Coverage by Age 24 Months Among Children Born in 2021 and 2022—United States, 2022–2024 — Confirms a declining hepatitis B birth-dose trend but reports a 1.8-percentage-point decline between compared cohorts.
Helicobacter pylori and Cancer — Supports the gastric-cancer link and benefits of eradication while noting limits on widespread testing and antibiotic-resistance concerns.
About Epstein-Barr Virus — Supports the statement that about nine in ten adults show evidence of current or past EBV infection.
HIV Infection and Cancer Risk — Supports the immune-suppression mechanism and reduced incidence of certain cancers with antiretroviral therapy.
Human Papillomavirus Vaccine — Supports HPV-associated cancer prevention and evidence that vaccination reduces invasive cancer incidence.
Recent advances in Epstein–Barr virus vaccines development from mechanistic exploration to clinical translation — Peer-reviewed review confirming that no EBV vaccine is licensed and multiple vaccine platforms are under development.

This assesses evidence and presentation; it is not an overall truth verdict.

Reassess

⚠ Paid reassessment incurs a charge. Opening this page does not start a run or incur a charge.

To request a new assessment, sign in to My library, watch this record, and select Request new assessment. Requests await separate approval and do not themselves start a paid run.

A new assessment may differ. Earlier published results remain in history.

Open My library

Assessment history

Published assessment trend

Available public snapshots only; this is not a count of all executions. Corrections may include earlier scores. Gaps mean not scored or not recorded. Different scores do not establish changed source evidence.

Evidence support — solid blueBalance & context — dashed purpleTransparency — dotted green

Reassess ⚠

Recorded public scores (0–100)
Date	Evidence support	Balance & context	Transparency
2026-10-14 (current)	84	73	74